Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Queensland Health
McKesson
Boehringer Ingelheim
QuintilesIMS
Medtronic
Novartis
Johnson and Johnson
Cipla
Argus Health

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,071,537

« Back to Dashboard

Which drugs does patent 6,071,537 protect, and when does it expire?


Patent 6,071,537 protects QSYMIA and is included in one NDA. There has been one Paragraph IV challenge on Qsymia.

This patent has twenty-nine patent family members in twenty-four countries.

Summary for Patent: 6,071,537

Title: Anticonvulsant derivatives useful in treating obesity
Abstract:A method for treating obesity comprising administering a therapeutically effective amount of a compound of the formula: ##STR1## is disclosed.
Inventor(s): Shank; Richard P. (Blue Bell, PA)
Assignee: Ortho Pharmaceutical Corporation (Raritan, NJ)
Application Number:08/881,009
Patent Claim Types:
see list of patent claims
Use; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-001Jul 17, 2012RXYesNo► Subscribe► Subscribe USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-002Jul 17, 2012RXYesNo► Subscribe► Subscribe USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-003Jul 17, 2012RXYesNo► Subscribe► Subscribe USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-004Jul 17, 2012RXYesYes► Subscribe► Subscribe USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,071,537

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway317754► Subscribe
Norway986052► Subscribe
Japan2000514425► Subscribe
South Korea20000022253► Subscribe
Israel127715► Subscribe
Hungary226775► Subscribe
Hungary0001192► Subscribe
Hong Kong1018743► Subscribe
Spain2184127► Subscribe
European Patent Office0915697► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Julphar
Novartis
Cipla
Medtronic
AstraZeneca
Moodys
Chinese Patent Office
Colorcon
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot